SEARCH

SEARCH BY CITATION

References

  • 1
    von der Maase H, Hansen S, Roberts J, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18: 3068-3077.
  • 2
    Loehrer P, Einhorn L, Elson P, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10: 1066-1073.
  • 3
    von der Maase H, Sengelov L, Roberts J, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
  • 4
    Saxman S, Propert K, Einhorn L, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol. 1997; 15: 2564-2569.
  • 5
    Raghavan D. Advanced bladder and urothelial cancers. Eur J Cancer. 2000; 36 ( suppl 2): 1-6.
  • 6
    Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997; 15: 589-593.
  • 7
    McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. J Clin Oncol. 1997; 15: 2449-2455.
  • 8
    Krege S, Rembrink V, Borgermann CH, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol. 2001; 165: 67-71.
  • 9
    Gallagher D, Milowsky M, Bajorin D. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer. 2008; 113: 1284-1293.
  • 10
    Wulfing C, Machiels J, Richel D, et al. A single arm, multicenter, open label, phase II study of lapatinib as treatment of patients with locally advanced/metastatic transitional cell carcinoma of the urothelial tract [abstract]. Proc Am Soc Clin Oncol. 2005; 23( part I): 401s. Abstract 4594.
  • 11
    Philips G, Halabi S, Sanford B, Bajorin D, Small E. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2008; 101: 20-25.
  • 12
    Xia G, Kumar S, Hawes D, et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006; 175: 1245-1252.
  • 13
    Inoue K, Slaton J, Davis D, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res. 2000; 6: 2635-2643.
  • 14
    Osai W, Ng C, Pagliaro L. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs. 2008; 19: 427-429.
  • 15
    Hahn O, Stadler W. Sorafenib. Curr Opin Oncol. 2006; 18: 615-621.
  • 16
    Escudier B, Eisen T, Stadler W, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 357: 125-134.
  • 17
    Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
  • 18
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 19
    Bajorin D, Dodd P, Mazumdar M, et al. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17: 3173-3181.
  • 20
    Bellmunt J, von der Maase H, Theodore C, et al. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU) [abstract]. J Clin Oncol. 2008; 26( suppl): 257. Abstract 5028.
  • 21
    Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007; 25: 2218-2224.
  • 22
    Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994; 69: 1120-1125.
  • 23
    Petrylak D, Faulkner J, Van Veldhuizen P, Mansukhani M, Crawford E. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: a Southwest Oncology Group Trial. Proc Am Soc Clin Oncol. 2005; 22: 403.
  • 24
    Gallagher D, Milowsky M, Gerst S, et al. Final results of a phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma [abstract]. J Clin Oncol. 2008; 26: 270. Abstract 5082.